Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

595 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized controlled trial investigating the survival benefit of dose-intensified multidrug combination chemotherapy (LSG9) for intermediate- or high-grade non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9002.
Kinoshita T, Hotta T, Tobinai K, Kobayashi T, Ishizuka N, Tomonaga M, Sai T, Ohno Y, Kasai M, Ogura M, Mikuni C, Toki H, Sano M, Masaki Y, Ohtsu T, Matsuno Y, Takenaka T, Shirakawa S, Shimoyama M; Japan Clinical Oncology Group. Kinoshita T, et al. Among authors: masaki y. Int J Hematol. 2004 Nov;80(4):341-50. doi: 10.1532/ijh97.04085. Int J Hematol. 2004. PMID: 15615259 Clinical Trial.
Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan.
Shimada K, Matsue K, Yamamoto K, Murase T, Ichikawa N, Okamoto M, Niitsu N, Kosugi H, Tsukamoto N, Miwa H, Asaoku H, Kikuchi A, Matsumoto M, Saburi Y, Masaki Y, Yamaguchi M, Nakamura S, Naoe T, Kinoshita T. Shimada K, et al. Among authors: masaki y. J Clin Oncol. 2008 Jul 1;26(19):3189-95. doi: 10.1200/JCO.2007.15.4278. Epub 2008 May 27. J Clin Oncol. 2008. PMID: 18506023
Does more intensive therapy have effects on mantle cell lymphoma? A clinical experience from the Lymphoma Treatment Study Group in Japan.
Miura K, Takasaki H, Tsujimura H, Kanno M, Maeda Y, Tomita N, Takai K, Masaki Y, Takizawa J, Mori H, Terasaki Y, Yoshida T, Takeuchi J, Motomura S. Miura K, et al. Among authors: masaki y. Int J Hematol. 2011 May;93(5):684-686. doi: 10.1007/s12185-011-0845-4. Epub 2011 Apr 12. Int J Hematol. 2011. PMID: 21479980 No abstract available.
Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version.
Masaki Y, Kawabata H, Takai K, Kojima M, Tsukamoto N, Ishigaki Y, Kurose N, Ide M, Murakami J, Nara K, Yamamoto H, Ozawa Y, Takahashi H, Miura K, Miyauchi T, Yoshida S, Momoi A, Awano N, Ikushima S, Ohta Y, Furuta N, Fujimoto S, Kawanami H, Sakai T, Kawanami T, Fujita Y, Fukushima T, Nakamura S, Kinoshita T, Aoki S. Masaki Y, et al. Int J Hematol. 2016 Jun;103(6):686-92. doi: 10.1007/s12185-016-1979-1. Epub 2016 Mar 18. Int J Hematol. 2016. PMID: 27084250
Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707.
Maeda Y, Nishimori H, Yoshida I, Hiramatsu Y, Uno M, Masaki Y, Sunami K, Masunari T, Nawa Y, Yamane H, Gomyo H, Takahashi T, Yano T, Matsuo K, Ohshima K, Nakamura S, Yoshino T, Tanimoto M. Maeda Y, et al. Among authors: masaki y. Haematologica. 2017 Dec;102(12):2097-2103. doi: 10.3324/haematol.2017.167742. Epub 2017 Sep 29. Haematologica. 2017. PMID: 28971899 Free PMC article. Clinical Trial.
Improved prognosis of extranodal NK/T cell lymphoma, nasal type of nasal origin but not extranasal origin.
Yamaguchi M, Suzuki R, Miyazaki K, Amaki J, Takizawa J, Sekiguchi N, Kinoshita S, Tomita N, Wada H, Kobayashi Y, Niitsu N, Ando T, Maeda T, Saito B, Matsuoka H, Sakai R, Kubota N, Masaki Y, Kameoka Y, Asano N, Oguchi M, Katayama N. Yamaguchi M, et al. Among authors: masaki y. Ann Hematol. 2019 Jul;98(7):1647-1655. doi: 10.1007/s00277-019-03689-9. Epub 2019 Apr 19. Ann Hematol. 2019. PMID: 31001658 Clinical Trial.
595 results